Daniel leads the BioPharma Business at Guardant Health, focused on partnerships with biopharmaceutical companies across the continuum of care using Guardant’s Digital Sequencing platform. Daniel brings more than a twenty years of experience in lifesciences across business development, strategy, and operations. Previously, Daniel served in roles at MyoKardia, Onyx Pharmaceuticals, McKinsey & Company, and Genentech. He holds an MBA from the University of Pennsylvania’s Wharton School and an MA Hons. in Natural Sciences from the University of Cambridge.
3:00 PM - 4:00 PM (PDT)
Wednesday, June 15
In 2021, cancer diagnostics achieved a long-discussed “Holy Grail” milestone with…